A.A. TYURINA, A.G. YASCHUK, A.G. IMELBAEVA, O.V. YAKOVLEVA

Bashkir State Medical University, 3 Lenin St., Ufa, Russian Federation, 450000

 Tyurina A.A. ― postgraduate student of the Department of Obstetrics and Gynecology №2, e-mail: alla.tyurina2016@yandex.ru, ORCID ID: 0000-0001-6657-8081

Yaschuk A.G. ― D. Med. Sc., Professor, Head of the Department of Obstetrics and Gynecology №2, e-mail: alfiya_galimovna@mail.ru, ORCID ID: 0000-0003-2645-1662

Imelbaeva A.G. ― assistant at the Department of Obstetrics and Gynecology №2, e-mail: albina321093@rambler.ru, ORCID ID: 0000-0002-0558-1364

Yakovleva O.V. ― postgraduate student of the Department of Obstetrics and Gynecology №2, e-mail: olgayakov-leva@mail.ru, ORCID ID: 0000-0002-0429-2368

Objective ― to summarize the data of modern literature on the role of progesterone and tissue growth factors in the pathogenesis of uterine myomas.

Material and methods. Analysis of data from periodic sources of literature in relation to uterine fibroids. Studies that examine the genomic and non-genomic effects of progesterone receptors and their role in promoting the growth of myomatous nodes have been collected and systematized in this review. Studies on the effects of various progesterone receptor modulators for the treatment of uterine myomas have also been highlighted.

Results. Uterine leiomyoma is a benign tumor that originates from the myometrium. Research data show that ovarian steroid hormones, in particular progesterone, are the main regulators of development and growth of myomas. The effect of progesterone in fibroids involves the classical effects of nuclear receptors on gene regulation, but there is increasing evidence that the signaling pathways are directly activated by progesterone receptors (PR) and that PR can interact with signaling systems of growth factors, promoting proliferation and maintenance of uterine myomas.

Conclusion. Better understanding of the mechanisms that provide progesterone-dependent growth of myomatous nodes is necessary to create the most effective and safe methods of treatment for this widespread disease.

Key words: progesterone receptors, uterine leiomyoma, progesterone.

(For citation: Tyurina A.A., Yaschuk A.G., Imelbaeva A.G., Yakovleva O.V. The role of progesterone and tissue growth factors in pathogenesis of uterine leiomyomas. Practical Medicine. 2018)

REFERENCES

1. Sidorova I.S., Unanyan A.L., Ageev M.B. et al. The current status of the issue of pathogenesis, clinic, diagnosis and treatment of uterine fibroids in women of reproductive age. Akusherstvo. Ginekologiya. Reproduktsiya, 2012, vol. 6, no. 4 (in Russ.).
2. Flynn M., Jamison M., Datta S., Myers E. Health care resource use for uterine fibroid tumors in the United States. Am. J. Obstet. Gynecol, 2006, 195, pp. 955-64. [PubMed: 16723104]
3. Peddada S.D., Laughlin S.K., Miner K., et al. Growth of uterine leiomyomata among premenopausal black andwhite women. Proc. Natl. Acad. Sci. U S A, 2008, 105, pp. 19887-92. [PubMed: 19047643]
4. Kjerulff K.H., Langenberg P., Seidman J.D., et al. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J. Reprod. Med, 1996, 41, pp. 483-90. [PubMed: 8829060]
5. Sidorova I.S., Unanyan A.L., Kogan E.A., Guriev T.D. Uterine fibroids in young patients: clinical and pathogenetic features. Akusherstvo, ginekologiya i reproduktsiya, 2010, no. 1, pp. 16-20 (in Russ.).
6. Chiaffarino F., Parazzini F., La Vecchia C., et al. Diet and uterinemyomas. Obstet. Gynecol, 1999, 94, pp. 395-8. [PubMed: 10472866]
7. Nagata C., Nakamura K., Oba S., et al. Association of intakes of fat, dietary fibre, soya isoflavones and alcohol with uterine fibroids in Japanese women. Br. J. Nutr, 2009, 101, pp. 1427-31. [PubMed: 19459228]
8. Sayed G.H., Zakherah M.S., El-Nashar S.A., Shaaban M.M. A randomized clinical trial of alevonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int. J. Gynaecol. Obstet, 2011, 112, pp. 126-30. [PubMed: 21092958]
9. Soysal S., Soysal M.E. The efficacy of levonorgestrel-releasing intrauterine device in selected casesof myoma-related menorrhagia: a prospective controlled trial. Gynecol. Obstet. Invest, 2005, 59, pp. 29-35. [PubMed: 15377823]
10. Wildemeersch D., Schacht E. The effect on menstrual blood loss in women with uterine fibroidsof a novel «frameless» intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol, 2002, 102, pp. 74-9. [PubMed: 12039094]
11. Freed M.M., Spies J.B. Uterine artery embolization for fibroids: a review of current outcomes. Semin. Reprod. Med, 2010, 28, pp. 235-41. [PubMed: 20414846]
12. Al Hilli M.M., Stewart E.A. Magnetic resonance-guided focused ultrasound surgery. Semin. Reprod. Med, 2010, 28, pp. 242-9. [PubMed: 20414847]
13. Moravek M., Yin P., Ono M., et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Human Reproduction Update, 2014, 21 (1), pp. 1-12.
14. Cermik D., Arici A., Taylor H.S. Coordinated regulation of HOX gene expression in myometriumand uterine leiomyoma. Fertil Steril, 2002, 78, pp. 979–84. [PubMed: 12413981]
15. Neiger R., Sonek J.D., Croom C.S., Ventolini G. Pregnancy-related changes in the size of uterineleiomyomas. J. Reprod. Med, 2006, 51, pp. 671-4. [PubMed: 17039693]
16. Hammoud A.O., Asaad R., Berman J., et al. Volume change of uterine myomas during pregnancy: do myomas really grow?. J. Minim. Invasive Gynecol, 2006, 13, pp. 386-90. [PubMed: 16962519]
17. Buyanova S.N., Yudina N.V., Gukasyan S.A. Modern aspects of the growth of uterine fibroids. Rossiyskiy vestnik akushera-ginekologa, 2012, 12 (4), pp. 42-48 (in Russ.).
18. Lamminen S., Rantala I., Helin H., et al. Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol. Obstet. Invest, 1992, 34, pp. 111-4. [PubMed: 1356890]
19. Grigorieva V., Chen-Mok M., Tarasova M., Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril, 2003, 79, pp. 1194-8. [PubMed: 12738516]
20. Tasci Y., Caglar G.S., Kayikcioglu F. et al. Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus. Arch. Gynecol. Obstet, 2009, 280, pp. 39-42. [PubMed: 19066923]
21. Orbo A., Arnes M., Pettersen I. et al. Down regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system. Acta Obstet. Gynecol. Scand, 2010, 89, pp. 1438-46. [PubMed: 20955098]
22. Jarvela I., Tekay A., Jouppila P. The effect of a levonorgestrel-releasing intrauterine system onuterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum. Reprod, 1998, 13, pp. 3379-83. [PubMed: 9886518]
23. Xu Q., Qiu L., Zhu L., Luo L., Xu C. Levonorgestrel inhibits proliferation and induces apoptosis inuterine leiomyoma cells. Contraception, 2010, 82, pp. 301-8. [PubMed: 20705162]
24. Bagaria M., Suneja A., Vaid N.B. et al. Low-dose mifepristone in treatment ofuterine leiomyoma: a randomised double-blind placebo-controlled clinical trial. Aust N Z J. Obstet. Gynaecol, 2009, 49, pp. 77-83. [PubMed: 19281585]
25. Engman M., Granberg S., Williams A.R. et al. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum. Reprod, 2009, 24, pp. 1870-9. [PubMed: 19389793]
26. Feng C., Meldrum S., Fiscella K. Improved quality of life is partly explained by fewer symptomsafter treatment of fibroids with mifepristone. Int. J. Gynaecol. Obstet, 2010, 109, pp. 121-4. [PubMed:20132932]
27. Fiscella K., Eisinger S.H., Meldrum S. et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet. Gynecol, 2006, 108, pp. 1381-7. [PubMed: 17138770]
28. Morikawa A., Ohara N., Xu Q. et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis incultured human uterine leiomyoma cells through up-regulating extracellular matrixmetalloproteinase inducer. Hum Reprod, 2008, 23, pp. 944-51. [PubMed: 18281245]
29. Ohara N., Morikawa A., Chen W. et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod. Sci, 2007, 14, pp. 20-7. [PubMed: 18089606]
30. Sasaki H., Ohara N., Xu Q., et al. A novelselective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J. Clin. Endocrinol. Metab, 2007, 92, pp. 616-23. [PubMed: 17105846]
31. Xu Q., Ohara N., Chen W. et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in culturedhuman uterine leiomyoma cells. Hum Reprod, 2006, 21, pp. 2408-16. [PubMed: 16720624]
32. Xu Q., Ohara N., Liu J. et al. Progesterone receptormodulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured humanuterine leiomyoma cells. Mol. Hum. Reprod, 2008, 14, pp. 181-91. [PubMed: 18216291]
33. Maruo T., Ohara N., Matsuo H. et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception, 2007, 75, pp. S99-103. [PubMed: 17531625]
34. Levens E.D., Potlog-Nahari C., Armstrong A.Y. et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol, 2008, 111, pp. 1129-36. [PubMed: 18448745]
35. Spitz I.M. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr. Opin. Obstet. Gynecol, 2009, 21, pp. 318-24. [PubMed: 19602929]
36. Horne F.M., Blithe D.L. Progesterone receptor modulators and the endometrium: changes and consequences. Hum. Reprod. Update, 2007, 13, pp. 567-80. [PubMed: 17630398]
37. Baird D.T., Brown A., Critchley H.O. et al. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod, 2003, 18, pp. 61-8. [PubMed:12525442]
38. Narvekar N., Cameron S., Critchley H.O. et al. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J. Clin. Endocrinol. Metab, 2004, 89, pp. 2491-7. [PubMed: 15126582]
39. Stratton P., Levens E.D., Hartog B. et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril, 2010, 93, pp. 2035-41. [PubMed: 19200989]
40. Robinson-Rechavi M., Escriva Garcia H., Laudet V. The nuclear receptor superfamily. J. Cell Sci, 2003, 116, pp. 585-6. [PubMed: 12538758]
41. Hodges L.C., Houston K.D., Hunter D.S. et al. Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands inuterine leiomyoma cells. Mol Cell Endocrinol, 2002, 196, pp. 11-20. [PubMed: 12385821]
42. Hassan M.H., Salama S.A., Arafa H.M. et al. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J. Clin. Endocrinol. Metab, 2007, 92, pp. 3949-57. [PubMed:17635941]
43. Ishikawa H., Ishi K., Serna V.A. et al. Progesterone is essential formaintenance and growth of uterine leiomyoma. Endocrinology, 2010, 151, pp. 2433-42. [PubMed:20375184]
44. Shozu M., Murakami K., Inoue M. Aromatase and leiomyoma of the uterus. Semin. Reprod. Med, 2004, 22, pp. 51-60. [PubMed: 15083381]
45. Parsanezhad M.E., Azmoon M., Alborzi S. et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril, 2009, 93, pp. 192-8. [PubMed: 19135657]
46. Worda C., Sator M.O., Schneeberger C. et al. Influence of the catechol-O-methyltransferase (COMT) codon 158 polymorphism on estrogen levels in women. Hum. Reprod, 2003, 18, pp. 262-6. [PubMed: 12571159]
47. Salama S.A., Kamel M.W., Botting S. et al. Catechol-omethyltransferase expression and 2-methoxyestradiol affect microtubule dynamics and modify steroid receptor signaling inleiomyoma cells. PLoS One, 2009, 4, p. e7356. [PubMed: 19809499]
48. Di X., Yu L., Moore A.B. et al. A low concentration of genistein induces estrogen receptor-alpha and insulin-like growth factor-I receptor interactions and proliferation in uterine leiomyoma cells. Hum Reprod, 2008, 23, pp. 1873-83. [PubMed: 18492705]
49. Yu L., Moore A.B., Dixon D. Receptor tyrosine kinases and their hormonal regulation in uterineleiomyoma. Semin. Reprod. Med, 28, pp. 250-9. [PubMed: 20414848]
50. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell, 2000, 103, pp. 211-25. [PubMed:11057895]
51. Peng L., Wen Y., Han Y. et al. Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity inuterine leiomyomas. Fertil Steril, 2009, 91, pp. 2664-75. [PubMed: 18439583]
52. Yu L., Saile K., Swartz C.D. et al. Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation inthuman uterine leiomyomas. Mol Med, 2008, 14, pp. 264-75. [PubMed: 18231572]
53. Arici A., Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-beta1 in human myometrium and leiomyoma. Am. J. Obstet. Gynecol, 2003, 188, pp. 76-83. [PubMed: 12548199]
54. Suo G., Jiang Y., Cowan B., Wang J.Y. Platelet-derived growth factor C is upregulated in humanuterine fibroids and regulates uterine smooth muscle cell growth. Biol. Reprod, 2009, 81, P. 749-58. [PubMed: 19553600]
55. Lee B.S., Nowak R.A. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. Clin. Endocrinol. Metab, 2001, 86, pp. 913-20. [PubMed: 11158066].
56. Shushan A., Rojansky N., Laufer N., et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Reprod, 2004, 19, pp. 1957-67. [PubMed: 15205403]
57. Wang J., Ohara N., Wang Z., et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Reprod, 2006, 21, pp. 1869-77. [PubMed: 16613890]
58. Yamada T., Nakago S., Kurachi O., et al. Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod, 2004, 19, pp. 815-21. [PubMed: 15033949]
59. Ying Z., Weiyuan Z. Dual actions of progesterone on uterine leiomyoma correlate with the ratioof progesterone receptor A:B. Gynecol. Endocrinol, 2009, 25, pp. 520-3. [PubMed: 19499404]
60. Liang M., Wang H., Zhang Y. et al. Expression and functional analysis of plateletderived growth factor in uterine leiomyomata. Cancer Biol. Ther, 2006, 5, pp. 28-33. [PubMed:16294022]
61. Hwu Y.M., Li S.H., Lee R.K. et al. Increased expression of platelet-derivedgrowth factor C messenger ribonucleic acid in uterine leiomyomata. Fertil Steril, 2008, 89, pp. 468-71. [PubMed: 17482170]
62. Kayisli U.A., Berkkanoglu M., Kizilay G., et al. Expression of proliferative and preapoptotic molecules in human myometrium and leiomyoma throughout the menstrual cycle. Sci, 2007, 14, pp. 678-86. [PubMed: 18000229]
63. Taylor D., Holthouser K., Segars J. and Leppert P. (2015). Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management. F1000 Research.